Introduction {#H1-1-ZLD190015}
============

Cardiac arrest (CA) remains a global health challenge with high rates of mortality and morbidity.^[@zld190015r1],[@zld190015r2]^ Furthermore, recovery from CA without residual neurologic deficit is limited. Consequently, the burden of CA on the US health care system is increasing.

Thirty-day readmissions are costly and associated with poor outcomes.^[@zld190015r3]^ However, there is a paucity of data regarding the readmission characteristics of CA, and previous studies have mostly focused on older populations.^[@zld190015r4]^ Therefore, further understanding of readmission after CA is needed to allow institutions to focus already limited resources and prevent unnecessary readmissions. We aimed to investigate contemporary rate, timing, causes, and risk factors associated with 30-day readmissions after CA.

Methods {#H1-2-ZLD190015}
=======

This cohort study used data from the Nationwide Readmissions Database (NRD) from 2010 to 2014. Data analysis was performed from January 1, 2010, to November 30, 2014. The NRD collects annual discharge data and enables nationally representative readmission analyses.^[@zld190015r5]^ All hospitalizations associated with either out-of-hospital CA or in-hospital CA were selected based on the *International Classification of Diseases, Ninth Revision, Clinical Modification* code 427.5. Among those with CA, ventricular tachycardia and ventricular fibrillation were identified by codes 427.1 and 427.4, respectively. Pulseless electrical activity or asystole arrests were defined as CA without concomitant ventricular arrhythmia. The primary outcome of interest was 30-day all-cause readmission. To identify independent risk factors associated with 30-day readmission following discharge after CA, we created a multivariable Cox proportional hazards regression model. The Weill Cornell Medicine institutional review board deemed this study exempt because the NRD is a publicly available database containing deidentified patient information. All analyses were performed using SAS statistical software version 9.4 (SAS Institute). All tests were 2-sided, with *P* \< .05 indicating statistical significance. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology ([STROBE](http://www.equator-network.org/reporting-guidelines/strobe/)) reporting guideline.

Results {#H1-3-ZLD190015}
=======

There were 251 346 patients who survived the CA-related index hospitalization. Median (interquartile range) age was 64.8 (53.7-75.8) years, and 106 831 participants (42.5%) were women ([Table 1](#zld190015t1){ref-type="table"}). Among CA survivors, 49 305 (19.6%) were readmitted within 30 days after discharge. While 30-day readmission rate was higher in the cohort with pulseless electrical activity or asystole than in the cohort with ventricular tachycardia or ventricular fibrillation (20.3% vs 18.3%; difference, 2.0%; 95% CI, 1.7%-2.4%; *P* \< .001), the median (interquartile range) time to readmission was 9 (4-18) days for both cohorts.

###### Baseline Individual- and Hospital-Level Characteristics for Cardiac Arrest Survivors Stratified by Causative Rhythm

  Characteristic                                                      No. (%)                                                                                                 
  ------------------------------------------------------------------- ------------------ ------------------ ------------------ -------- ------------------ ------------------ --------
  No. of patients                                                     251 346            69 358 (81.7)      15 496 (18.3)               132 683 (79.7)     33 809 (20.3)      
  Age, median (IQR), y                                                64.8 (53.7-75.8)   62.6 (52.8-72.8)   65.2 (55.2-74.9)   \<.001   66.1 (54.3-77.2)   66.4 (55.6-76.8)   .42
  Female                                                              106 831 (42.5)     23 152 (33.4)      5682 (36.7)        \<.001   61 572 (46.4)      16 425 (48.6)      \<.001
  ST-elevation myocardial infarction                                  32 584 (13.0)      19 125 (27.6)      3368 (21.7)        \<.001   8295 (6.3)         1796 (5.3)         \<.001
  Pulmonary embolism                                                  8563 (3.4)         1403 (2.0)         393 (2.5)          .07      5423 (4.1)         1344 (4.0)         .62
  Coma                                                                9790 (3.9)         2942 (4.2)         486 (3.1)          \<.001   5328 (4.0)         1034 (3.1)         \<.001
  Hypertension                                                        153 419 (61.0)     41 415 (59.7)      9613 (62.0)        .004     80 500 (60.7)      21 890 (64.7)      \<.001
  Diabetes                                                            83 635 (33.3)      19 518 (28.1)      5502 (35.5)        \<.001   44 589 (33.6)      14 026 (41.5)      \<.001
  Coronary artery disease                                             104 277 (41.5)     40 067 (57.8)      8812 (56.9)        .26      43 323 (32.7)      12 075 (35.7)      \<.001
  Myocardial infarction                                               19 831 (7.9)       7326 (10.6)        1631 (10.5)        .94      8424 (6.3)         2450 (7.2)         \<.001
  Percutaneous coronary intervention                                  17 686 (7.0)       6350 (9.2)         1390 (9.0)         .70      7794 (5.9)         2153 (6.4)         .08
  Coronary artery bypass graft                                        16 437 (6.5)       4908 (7.1)         1204 (7.8)         .11      8090 (6.1)         2234 (6.6)         .07
  Congestive heart failure                                            100 016 (39.8)     30 327 (43.7)      8760 (56.5)        \<.001   45 980 (34.7)      14947 (44.2)       \<.001
  Cardiac arrest                                                      5523 (2.2)         2378 (3.4)         379 (2.4)          \<.001   2315 (1.7)         451 (1.3)          .002
  Peripheral vascular disease                                         20 980 (8.3)       4977 (7.2)         1608 (10.4)        \<.001   10 792 (8.1)       3603 (10.7)        \<.001
  Pulmonary hypertension                                              18 339 (7.3)       4446 (6.4)         1384 (8.9)         \<.001   9562 (7.2)         2947 (8.7)         \<.001
  Chronic pulmonary disease                                           49 776 (19.8)      11 565 (16.7)      3377 (21.8)        \<.001   26 517 (20.0)      8318 (24.6)        \<.001
  Chronic kidney disease                                              49 755 (19.8)      11 057 (15.9)      3657 (23.6)        \<.001   26 303 (19.8)      8737 (25.8)        \<.001
  Hemodialysis                                                        26 341 (10.5)      4509 (6.5)         2160 (13.9)        \<.001   13 720 (10.3)      5951 (17.6)        \<.001
  Anemia                                                              71 400 (28.4)      16 135 (23.3)      4696 (30.3)        \<.001   38 499 (29.0)      12 070 (35.7)      \<.001
  Atrial fibrillation                                                 65 876 (26.2)      18 934 (27.3)      4792 (30.9)        \<.001   32 881 (24.8)      9269 (27.4)        \<.001
  Coagulopathy                                                        36 886 (14.7)      9171 (13.2)        2506 (16.2)        \<.001   19 516 (14.7)      5694 (16.8)        \<.001
  Obesity                                                             37 946 (15.1)      10 306 (14.9)      2425 (15.7)        .18      19 677 (14.8)      5537 (16.4)        \<.001
  Pulmonary circulation disorders                                     15 909 (6.3)       2343 (3.4)         887 (5.7)          \<.001   9676 (7.3)         3003 (8.9)         \<.001
  Valvular heart disease                                              15 116 (6.0)       2862 (4.1)         960 (6.2)          \<.001   8781 (6.6)         2513 (7.4)         .005
  Elixhauser Comorbidity Index score \>4                              141 903 (56.5)     33 711 (48.6)      9739 (62.8)        \<.001   75 425 (56.8)      23 028 (68.1)      \<.001
  Procedures performed                                                                                                                                                        
  Coronary angiography                                                76 621 (30.5)      40 815 (58.8)      7632 (49.3)        \<.001   22 684 (17.1)      5489 (16.2)        .04
  Percutaneous coronary intervention                                  36 994 (14.7)      21 626 (31.2)      3958 (25.5)        \<.001   9341 (7.0)         2070 (6.1)         .002
  Intra-aortic balloon pump                                           13 546 (5.4)       7062 (10.2)        1647 (10.6)        .41      3753 (2.8)         1084 (3.2)         .06
  Percutaneous left ventricular assist device                         998 (0.4)          504 (0.7)          147 (0.9)          .10      288 (0.2)          59 (0.2)           .38
  Targeted temperature management                                     7190 (2.9)         4033 (5.8)         583 (3.8)          \<.001   2102 (1.6)         473 (1.4)          .18
  Teaching hospital[^a^](#zld190015t1n1){ref-type="table-fn"}         140 812 (56.0)     40 153 (57.9)      8971 (57.9)        \>.99    72 685 (54.8)      19 003 (56.2)      .01
  Urban hospital location[^b^](#zld190015t1n2){ref-type="table-fn"}   137 506 (54.7)     37 559 (54.2)      8931 (57.6)        \<.001   71 478 (53.9)      19 538 (57.8)      \<.001
  Length of hospital stay, median (IQR), d                            10.1 (4.8-19.6)    8.8 (4.6-16.3)     12.2 (6.5-22.0)    \<.001   9.8 (4.4-19.8)     13.7 (7.0-24.7)    \<.001
  Prolonged hospital stay[^c^](#zld190015t1n3){ref-type="table-fn"}   65 184 (25.9)      13 563 (19.6)      4799 (31.0)        \<.001   34 842 (26.3)      11 979 (35.4)      \<.001

Abbreviations: IQR, interquartile range; PEA, pulseless electrical activity; VF, ventricular fibrillation or flutter; VT, ventricular tachycardia.

Nonteaching hospital as reference.

Rural hospital location as reference.

Length of stay days exceeding the 75th percentile (≥20 days) of the entire stay days.

Overall, approximately three-quarters (72.1%) of the 30-day readmissions were due to noncardiac causes, which were more common among patients with pulseless electrical activity or asystole than those with ventricular tachycardia or ventricular fibrillation (77.2% vs 61.4%; difference, 15.7%; 95% CI, 14.9%-16.6%; *P* \< .001). Among noncardiac causes, infectious etiology (pneumonia and sepsis) was most prevalent (18.9%), followed by chronic obstructive pulmonary disease or respiratory failure (13.3%). Heart failure and arrhythmia accounted for more than 50% of all cardiac causes of readmission. After adjusting for baseline characteristics, several comorbidities were independently associated with a higher risk of 30-day readmission across the rhythm cohorts ([Table 2](#zld190015t2){ref-type="table"}).

###### Risk Factors Associated With 30-Day Readmission After Cardiac Arrest--Related Index Hospitalization

  Covariate                                                           VT or VF           PEA or Asystole                                                                                                          
  ------------------------------------------------------------------- ------------------ ----------------- ---------------------------------------------- -------- ------------------ -------- ------------------ --------
  Female                                                              1.14 (1.07-1.21)   \<.001            1.05 (0.99-1.12)                               .13      1.08 (1.04-1.12)   \<.001   1.06 (1.02-1.11)   .002
  Chronic kidney disease receiving hemodialysis                       2.07 (1.92-2.24)   \<.001            1.56 (1.43-1.70)                               \<.001   1.70 (1.62-1.78)   \<.001   1.44 (1.36-1.52)   \<.001
  Prolonged hospital stay[^c^](#zld190015t2n3){ref-type="table-fn"}   1.71 (1.61-1.81)   \<.001            1.38 (1.30-1.48)                               \<.001   1.46 (1.40-1.52)   \<.001   1.35 (1.29-1.41)   \<.001
  History of congestive heart failure                                 1.58 (1.49-1.68)   \<.001            1.27 (1.20-1.36)                               \<.001   1.42 (1.37-1.48)   \<.001   1.19 (1.14-1.24)   \<.001
  Chronic kidney disease                                              1.53 (1.43-1.64)   \<.001            1.21 (1.12-1.30)                               \<.001   1.35 (1.29-1.41)   \<.001   1.17 (1.12-1.23)   \<.001
  Chronic pulmonary disease                                           1.34 (1.25-1.43)   \<.001            1.16 (1.08-1.25)                               \<.001   1.27 (1.21-1.33)   \<.001   1.18 (1.12-1.24)   \<.001
  Intra-aortic balloon pump                                           1.04 (0.94-1.16)   .41               NC[^d^](#zld190015t2n4){ref-type="table-fn"}   NC       1.13 (1.00-1.27)   .048     1.18 (1.04-1.34)   .01
  Peripheral vascular disease                                         1.43 (1.30-1.56)   \<.001            1.16 (1.06-1.27)                               .002     1.29 (1.21-1.38)   \<.001   1.11 (1.03-1.19)   .005
  Percutaneous coronary intervention                                  0.78 (0.73-0.83)   \<.001            1.13 (1.03-1.24)                               .007     0.88 (0.81-0.95)   .002     0.97 (0.87-1.08)   .57
  Diabetes                                                            1.35 (1.27-1.43)   \<.001            1.08 (1.01-1.15)                               .02      1.34 (1.29-1.40)   \<.001   1.12 (1.07-1.17)   \<.001
  Anemia                                                              1.37 (1.29-1.46)   \<.001            1.07 (1.00-1.14)                               .06      1.31 (1.26-1.37)   \<.001   1.06 (1.02-1.11)   .007
  Urban hospital location[^e^](#zld190015t2n5){ref-type="table-fn"}   1.14 (1.07-1.21)   \<.001            1.08 (1.01-1.15)                               .02      1.15 (1.10-1.20)   \<.001   1.06 (1.01-1.10)   .009
  Elixhauser Comorbidity Index score \>4                              1.68 (1.58-1.79)   \<.001            1.06 (0.97-1.15)                               .24      1.54 (1.48-1.60)   \<.001   1.06 (1.00-1.13)   .04
  Atrial fibrillation                                                 1.17 (1.10-1.24)   \<.001            1.01 (0.95-1.07)                               .79      1.13 (1.08-1.18)   \<.001   1.05 (1.01-1.10)   .03
  Hypertension                                                        1.09 (1.03-1.16)   .003              0.93 (0.87-0.99)                               .02      1.17 (1.12-1.22)   \<.001   0.99 (0.94-1.03)   .50
  Coronary angiography                                                0.71 (0.67-0.75)   \<.001            0.89 (0.83-0.95)                               \<.001   0.95 (0.90-1.00)   .04      0.98 (0.92-1.05)   .61
  History of cardiac arrest                                           0.72 (0.61-0.85)   \<.001            0.81 (0.69-0.96)                               .01      0.78 (0.67-0.92)   .003     0.77 (0.65-0.90)   .001
  Targeted temperature management                                     0.66 (0.57-0.77)   \<.001            0.76 (0.66-0.89)                               \<.001   0.90 (0.76-1.07)   .22      NC                 NC
  Coma                                                                0.76 (0.65-0.89)   \<.001            0.73 (0.62-0.84)                               \<.001   0.78 (0.70-0.86)   \<.001   0.75 (0.67-0.82)   \<.001

Abbreviations: HR, hazard ratio; NC, not calculated; PEA, pulseless electrical activity; VF, ventricular fibrillation or flutter; VT, ventricular tachycardia.

Univariate Cox proportional hazards regression model was created with an outcome of 30-day readmission for each covariate from [Table 1](#zld190015t1){ref-type="table"}.

Multivariable Cox proportional hazards regression model was created with an outcome of 30-day readmission including all covariates with *P* \< .10 in the univariate analysis, and the covariates with *P* \< .05 for either rhythm cohort are listed.

Length of stay days exceeding the 75th percentile (≥20 days) of the entire stay days.

Covariate with *P* ≥ .10 in the univariate analysis was not included in the multivariable analysis.

Rural hospital location as reference.

Discussion {#H1-4-ZLD190015}
==========

Given the high readmission rates and substantial economic burden associated with CA, nationwide efforts are necessary to develop strategies designed explicitly for CA survivors to reduce preventable readmissions. Of those readmitted within 30 days, more than half were readmitted within 9 days, especially for noncardiac causes. Close outpatient follow-up during the first 10 days after hospitalization may be an opportunity for clinicians to preemptively intervene on any evolving medical conditions and consequently prevent readmissions for CA survivors.^[@zld190015r6]^ Furthermore, patients with limited access to health care owing to their socioeconomic status have been shown to use the emergency department more as a primary source of care, which may lead to more readmissions. Therefore, multidisciplinary efforts to support the transition from inpatient to outpatient care with a readily available support system, including proper patient education, follow-up telephone calls, use of remote telemonitoring, clinician home visits, and postdischarge hotlines are potential strategies to consider. A limitation of our study is that we were unable to validate the codes for comorbidities from the *International Classification of Diseases, Ninth Revision, Clinical Modification*.

Conclusions {#H1-5-ZLD190015}
===========

This cohort study found increased rates of readmission among patients who survived CA. Early follow-up with health care professionals may enable timely management of both cardiac and general medical conditions and reduce preventable readmissions of CA survivors.
